[ TRANSACTION RECORD ]

Roche Holding AG Investment in Roche Immunology — 2023

VERIFIED VECTOR ID: 002190 · tx-286
M SOURCE NODE — FUNDER
Roche Holding AG
Healthcare Switzerland
$7,100,000,000
EQUITY
23/10/2023
Q DESTINATION NODE — RECIPIENT
Roche Immunology
SPV Switzerland
Amount (USD)
$7.1B
Flow Type
EQUITY
Transaction Date
23/10/2023
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity Roche Holding AG
AUM 255000
HQ Location Switzerland
Sector Healthcare
Recipient Profile [ Q ]
Entity Roche Immunology
Entity Type SPV
Jurisdiction Switzerland
Intelligence Note

Roche Holding AG entered into a definitive agreement to acquire Telavant for 7.1 billion dollars to gain access to a promising therapy for inflammatory bowel disease and immunology. This transaction includes the development and commercialization rights in the U.S. and Japan for specialized medical treatments. The deal underscores Roche’s commitment to expanding its biotech portfolio.

Σ
Primary Forensic Source https://www.roche.com/media/releases/med-cor-2023-10-23/
✓ SOURCE LINKED